• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在结肠炎期间,蛋白水解细菌的扩增通过 PAR2 外显子的切割放大炎症。

Proteolytic bacteria expansion during colitis amplifies inflammation through cleavage of the external domain of PAR2.

机构信息

Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.

IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France.

出版信息

Gut Microbes. 2024 Jan-Dec;16(1):2387857. doi: 10.1080/19490976.2024.2387857. Epub 2024 Aug 22.

DOI:10.1080/19490976.2024.2387857
PMID:39171684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11346554/
Abstract

Imbalances in proteolytic activity have been linked to the development of inflammatory bowel diseases (IBD) and experimental colitis. Proteases in the intestine play important roles in maintaining homeostasis, but exposure of mucosal tissues to excess proteolytic activity can promote pathology through protease-activated receptors (PARs). Previous research implicates microbial proteases in IBD, but the underlying pathways and specific interactions between microbes and PARs remain unclear. In this study, we investigated the role of microbial proteolytic activation of the external domain of PAR2 in intestinal injury using mice expressing PAR2 with a mutated N-terminal external domain that is resistant to canonical activation by proteolytic cleavage. Our findings demonstrate the key role of proteolytic cleavage of the PAR2 external domain in promoting intestinal permeability and inflammation during colitis. In wild-type mice expressing protease-sensitive PAR2, excessive inflammation leads to the expansion of bacterial taxa that cleave the external domain of PAR2, exacerbating colitis severity. In contrast, mice expressing mutated protease-resistant PAR2 exhibit attenuated colitis severity and do not experience the same proteolytic bacterial expansion. Colonization of wild-type mice with proteolytic PAR2-activating and worsens colitis severity. Our study identifies a previously unknown interaction between proteolytic bacterial communities, which are shaped by inflammation, and the external domain of PAR2 in colitis. The findings should encourage new therapeutic developments for IBD by targeting excessive PAR2 cleavage by bacterial proteases.

摘要

蛋白酶活性失衡与炎症性肠病 (IBD) 和实验性结肠炎的发生有关。肠道中的蛋白酶在维持内环境稳定方面发挥着重要作用,但黏膜组织暴露于过多的蛋白水解活性会通过蛋白酶激活受体 (PAR) 促进病理学发生。先前的研究表明微生物蛋白酶与 IBD 有关,但微生物与 PAR 之间的潜在途径和具体相互作用仍不清楚。在这项研究中,我们使用表达 PAR2 突变体 N 端外显子的小鼠,研究了微生物蛋白酶对 PAR2 外显子的蛋白水解激活在肠道损伤中的作用,该突变体对经典的蛋白水解切割激活具有抗性。我们的研究结果表明,PAR2 外显子的蛋白水解切割在促进结肠炎期间的肠道通透性和炎症中起着关键作用。在表达蛋白酶敏感型 PAR2 的野生型小鼠中,过度的炎症导致切割 PAR2 外显子的细菌分类群的扩张,从而加剧结肠炎的严重程度。相比之下,表达突变型蛋白酶抗性 PAR2 的小鼠表现出较轻的结肠炎严重程度,并且不会经历相同的蛋白水解细菌扩张。野生型小鼠的定植 和 可加重结肠炎的严重程度。我们的研究确定了一个以前未知的相互作用,即在结肠炎中,蛋白酶活性细菌群落受炎症影响,与 PAR2 的外显子相互作用。这些发现应鼓励通过靶向细菌蛋白酶对 PAR2 的过度切割来开发针对 IBD 的新治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da1/11346554/1aa734e5520f/KGMI_A_2387857_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da1/11346554/bfac9f8001fb/KGMI_A_2387857_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da1/11346554/74d4501a8b98/KGMI_A_2387857_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da1/11346554/28ba5bc0875b/KGMI_A_2387857_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da1/11346554/b02b8890aed3/KGMI_A_2387857_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da1/11346554/2f55934b423a/KGMI_A_2387857_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da1/11346554/1aa734e5520f/KGMI_A_2387857_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da1/11346554/bfac9f8001fb/KGMI_A_2387857_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da1/11346554/74d4501a8b98/KGMI_A_2387857_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da1/11346554/28ba5bc0875b/KGMI_A_2387857_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da1/11346554/b02b8890aed3/KGMI_A_2387857_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da1/11346554/2f55934b423a/KGMI_A_2387857_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0da1/11346554/1aa734e5520f/KGMI_A_2387857_F0006_OC.jpg

相似文献

1
Proteolytic bacteria expansion during colitis amplifies inflammation through cleavage of the external domain of PAR2.在结肠炎期间,蛋白水解细菌的扩增通过 PAR2 外显子的切割放大炎症。
Gut Microbes. 2024 Jan-Dec;16(1):2387857. doi: 10.1080/19490976.2024.2387857. Epub 2024 Aug 22.
2
Crohn's disease proteolytic microbiota enhances inflammation through PAR2 pathway in gnotobiotic mice.克罗恩病的蛋白水解微生物群通过共生小鼠中的 PAR2 途径增强炎症。
Gut Microbes. 2023 Jan-Dec;15(1):2205425. doi: 10.1080/19490976.2023.2205425.
3
Antagonism of protease-activated receptor 2 protects against experimental colitis.蛋白酶激活受体 2 的拮抗作用可预防实验性结肠炎。
J Pharmacol Exp Ther. 2012 Feb;340(2):256-65. doi: 10.1124/jpet.111.187062. Epub 2011 Oct 25.
4
Enterococcus-derived tyramine hijacks α-adrenergic receptor in intestinal stem cells to exacerbate colitis.肠球菌衍生的酪胺通过劫持肠道干细胞中的 α-肾上腺素能受体来加重结肠炎。
Cell Host Microbe. 2024 Jun 12;32(6):950-963.e8. doi: 10.1016/j.chom.2024.04.020. Epub 2024 May 23.
5
Enterococcus faecalis Gelatinase Mediates Intestinal Permeability via Protease-Activated Receptor 2.粪肠球菌明胶酶通过蛋白酶激活受体2介导肠道通透性。
Infect Immun. 2015 Jul;83(7):2762-70. doi: 10.1128/IAI.00425-15. Epub 2015 Apr 27.
6
Fecal let-7b and miR-21 directly modulate the intestinal microbiota, driving chronic inflammation.粪便 let-7b 和 miR-21 直接调节肠道微生物群,从而引发慢性炎症。
Gut Microbes. 2024 Jan-Dec;16(1):2394249. doi: 10.1080/19490976.2024.2394249. Epub 2024 Sep 3.
7
Serine proteases and protease-activated receptor 2 mediate the proinflammatory and algesic actions of diverse stimulants.丝氨酸蛋白酶和蛋白酶激活受体2介导多种刺激物的促炎和致痛作用。
Br J Pharmacol. 2014 Aug;171(16):3814-26. doi: 10.1111/bph.12738.
8
ASB3 expression aggravates inflammatory bowel disease by targeting TRAF6 protein stability and affecting the intestinal microbiota.ASB3 通过靶向 TRAF6 蛋白稳定性并影响肠道微生物群来加重炎症性肠病。
mBio. 2024 Sep 11;15(9):e0204324. doi: 10.1128/mbio.02043-24. Epub 2024 Aug 20.
9
PAR2 deficiency enhances myeloid cell-mediated immunosuppression and promotes colitis-associated tumorigenesis.PAR2 缺乏增强髓系细胞介导的免疫抑制作用,并促进结肠炎相关肿瘤发生。
Cancer Lett. 2020 Jan 28;469:437-446. doi: 10.1016/j.canlet.2019.11.015. Epub 2019 Nov 14.
10
Antagonism of the proinflammatory and pronociceptive actions of canonical and biased agonists of protease-activated receptor-2.蛋白酶激活受体-2的典型激动剂和偏向激动剂的促炎和促痛觉过敏作用的拮抗作用
Br J Pharmacol. 2016 Sep;173(18):2752-65. doi: 10.1111/bph.13554. Epub 2016 Aug 3.

引用本文的文献

1
Microbial proteases as emerging anti-inflammatory therapeutics: a comprehensive review.微生物蛋白酶作为新兴的抗炎疗法:全面综述
Arch Microbiol. 2025 Aug 19;207(9):229. doi: 10.1007/s00203-025-04409-w.
2
The Role of PAR2 in MASLD Progression and HCC Development.PAR2在代谢相关脂肪性肝病进展和肝癌发生中的作用
Int J Mol Sci. 2025 Jul 23;26(15):7076. doi: 10.3390/ijms26157076.
3
Cathepsin S: molecular mechanisms in inflammatory and immunological processes.组织蛋白酶S:炎症和免疫过程中的分子机制

本文引用的文献

1
Nucleic acid sensing promotes inflammatory monocyte migration through biased coagulation factor VIIa signaling.核酸感应通过偏向性凝血因子 VIIa 信号促进炎症性单核细胞迁移。
Blood. 2024 Mar 7;143(10):845-857. doi: 10.1182/blood.2023021149.
2
Crohn's disease proteolytic microbiota enhances inflammation through PAR2 pathway in gnotobiotic mice.克罗恩病的蛋白水解微生物群通过共生小鼠中的 PAR2 途径增强炎症。
Gut Microbes. 2023 Jan-Dec;15(1):2205425. doi: 10.1080/19490976.2023.2205425.
3
The emerging roles of bacterial proteases in intestinal diseases.
Front Immunol. 2025 Jul 7;16:1600206. doi: 10.3389/fimmu.2025.1600206. eCollection 2025.
4
Deciphering complexity of GPCR signaling and modulation: implications and perspectives for drug discovery.解析G蛋白偶联受体信号传导与调节的复杂性:对药物发现的启示与展望
Clin Sci (Lond). 2025 May 20;139(10):CS20245182. doi: 10.1042/CS20245182.
5
Microbial metabolism of food allergens determines the severity of IgE-mediated anaphylaxis.食物过敏原的微生物代谢决定了IgE介导的过敏反应的严重程度。
bioRxiv. 2025 Feb 19:2025.02.17.638013. doi: 10.1101/2025.02.17.638013.
6
Identification of a secreted protease from that induces intestinal pain and inflammation by cleavage of PAR.从……中鉴定出一种分泌型蛋白酶,该蛋白酶通过切割蛋白酶激活受体(PAR)诱导肠道疼痛和炎症。
bioRxiv. 2025 Jan 15:2025.01.15.633241. doi: 10.1101/2025.01.15.633241.
7
A New Strategy in Modulating the Protease-Activated Receptor 2 (Par2) in Autoimmune Diseases.一种调节自身免疫性疾病中蛋白酶激活受体2(Par2)的新策略。
Int J Mol Sci. 2025 Jan 6;26(1):410. doi: 10.3390/ijms26010410.
细菌蛋白酶在肠道疾病中的新兴作用。
Gut Microbes. 2023 Jan-Dec;15(1):2181922. doi: 10.1080/19490976.2023.2181922.
4
Targeting myeloid cell coagulation signaling blocks MAP kinase/TGF-β1-driven fibrotic remodeling in ischemic heart failure.靶向髓系细胞凝血信号可阻断 MAP 激酶/TGF-β1 驱动的缺血性心力衰竭中的纤维性重塑。
J Clin Invest. 2023 Feb 15;133(4):e156436. doi: 10.1172/JCI156436.
5
Activation of Human Platelets by Secreted Protease Staphopain A.分泌性蛋白酶葡萄球菌蛋白酶A对人血小板的激活作用
Pathogens. 2022 Oct 26;11(11):1237. doi: 10.3390/pathogens11111237.
6
Histamine production by the gut microbiota induces visceral hyperalgesia through histamine 4 receptor signaling in mice.肠道微生物群产生的组织胺通过小鼠 4 型组织胺受体信号引起内脏痛觉过敏。
Sci Transl Med. 2022 Jul 27;14(655):eabj1895. doi: 10.1126/scitranslmed.abj1895.
7
Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity.溃疡性结肠炎肠道微生物组的多组学分析将脆弱拟杆菌蛋白酶与疾病严重程度联系起来。
Nat Microbiol. 2022 Feb;7(2):262-276. doi: 10.1038/s41564-021-01050-3. Epub 2022 Jan 27.
8
Epithelial production of elastase is increased in inflammatory bowel disease and causes mucosal inflammation.弹性蛋白酶在炎症性肠病中的产生增加,并导致黏膜炎症。
Mucosal Immunol. 2021 May;14(3):667-678. doi: 10.1038/s41385-021-00375-w. Epub 2021 Mar 5.
9
Novel Fecal Biomarkers That Precede Clinical Diagnosis of Ulcerative Colitis.新型粪便生物标志物可在溃疡性结肠炎临床诊断前出现。
Gastroenterology. 2021 Apr;160(5):1532-1545. doi: 10.1053/j.gastro.2020.12.004. Epub 2020 Dec 10.
10
Macrophage protease-activated receptor 2 regulates fetal liver erythropoiesis in mice.巨噬细胞蛋白酶激活受体 2 调控小鼠胎肝内的红细胞生成。
Blood Adv. 2020 Nov 24;4(22):5810-5824. doi: 10.1182/bloodadvances.2020003299.